Wall Street Zen Upgrades Assembly Biosciences (NASDAQ:ASMB) to Strong-Buy

Assembly Biosciences (NASDAQ:ASMB) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Sunday.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research report on Thursday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Assembly Biosciences currently has an average rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Price Performance

ASMB opened at $27.70 on Friday. The stock has a market cap of $439.41 million, a P/E ratio of -37.43 and a beta of 1.11. The stock’s 50 day simple moving average is $27.93 and its 200 day simple moving average is $29.79. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The company had revenue of $42.47 million for the quarter, compared to analyst estimates of $7.42 million. Research analysts expect that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,319 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Assembly Biosciences during the 4th quarter worth about $147,000. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Assembly Biosciences during the fourth quarter valued at about $228,000. Finally, Virtus Investment Advisers LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter valued at about $251,000. Institutional investors own 19.92% of the company’s stock.

Key Assembly Biosciences News

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $50 target, which supports investor upside expectations. Article Title
• Positive Sentiment: The firm raised FY2026 estimates sharply (to $1.61 EPS) and put a large $3.51 EPS estimate for Q4‑2026 — signals HC Wainwright sees material near‑term revenue/earnings drivers that could deliver a positive earnings surprise in late 2026.
• Positive Sentiment: HC Wainwright also raised FY2028 estimates (to $0.32 EPS), suggesting a view that Assembly’s longer‑term pipeline/commercial prospects can generate positive earnings beyond the immediate quarters.
• Neutral Sentiment: The report includes a suite of multi‑year projections (Q1–Q4 2027, FY2030 estimates such as $3.23 EPS for FY2030) that provide modeling guidance but are farther out and carry higher uncertainty for near‑term stock moves.
• Negative Sentiment: HC Wainwright cut Q1, Q2 and Q3 2026 estimates (to roughly ($0.73), ($0.71), ($0.69) EPS respectively), indicating weaker expected near‑term performance that can pressure the stock until the company shows improving quarterly results.
• Negative Sentiment: The firm lowered FY2027 and FY2029 forecasts materially (FY2027 to ($0.64) from $1.44; FY2029 to ($2.83) from $3.09), pointing to increased downside risk in certain outyears and greater forecast volatility that can weigh on sentiment.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.